Back to search

Peptide record

TPDB21842

Antibacterial Anticancer Toxicity standard
14 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB21842
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia
standard
No
A 14-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia, with an available 3D structural model.
Sequence
KIVPAMICAVTKKC
Physicochemical Analysis
C66H121N17O16S3
RNDEQGHLFSWY
K
1504.97
9.80
3
0
7
+3
2.03
0.993
111.43
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
125
8.31
3
Residue Composition
number
2
A
0
R
0
N
0
D
2
C
0
E
0
Q
0
G
0
H
2
I
0
L
3
K
1
M
0
F
1
P
0
S
1
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 2 R: 0 N: 0 D: 0 C: 2 E: 0 Q: 0 G: 0 H: 0 I: 2 L: 0 K: 3 M: 1 F: 0 P: 1 S: 0 T: 1 W: 0 Y: 0 V: 2
Chemical Descriptors
14
C66H121N17O16S3
1504.97
9.80
+3
2.03
0.993
Evidence Records 15 records
Evidence 1 Activity

Activity

IC50
Toxicity
18 µg/mL
Cytotoxic
IC50 | 18 | µg/mL | target cell: Chinese hamster ovary cells CHO-K1

Target

Chinese hamster ovary cells CHO-K1

Source & Reference

NA
DBAASP
A novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics. | Int J Antimicrob Agents | 2018
Evidence 2 Activity

Activity

IC50
Toxicity
18 µg/mL
Cytotoxic
IC50 | 18 | µg/mL | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
A novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics. | Int J Antimicrob Agents | 2018
Evidence 3 Activity

Activity

IC50
Toxicity
20 µg/mL
Cytotoxic
IC50 | 20 | µg/mL | target cell: Chinese hamster ovary cells CHO-K1

Target

Chinese hamster ovary cells CHO-K1

Source & Reference

NA
DBAASP
A novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics. | Int J Antimicrob Agents | 2018
Evidence 4 Activity

Activity

IC50
Toxicity
20 µg/mL
Cytotoxic
IC50 | 20 | µg/mL | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
A novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics. | Int J Antimicrob Agents | 2018
Evidence 5 Activity

Activity

IC50
Toxicity
25 µg/mL
Cytotoxic
IC50 | 25 | µg/mL | target cell: Chinese hamster ovary cells CHO-K1

Target

Chinese hamster ovary cells CHO-K1

Source & Reference

NA
DBAASP
A novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics. | Int J Antimicrob Agents | 2018
Evidence 6 Activity

Activity

IC50
Toxicity
23 µg/mL
Cytotoxic
IC50 | 23 | µg/mL | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
A novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics. | Int J Antimicrob Agents | 2018
Evidence 7 Activity

Activity

IC50
Toxicity
28 µg/mL
Cytotoxic
IC50 | 28 | µg/mL | target cell: Chinese hamster ovary cells CHO-K1

Target

Chinese hamster ovary cells CHO-K1

Source & Reference

NA
DBAASP
A novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics. | Int J Antimicrob Agents | 2018
Evidence 8 Activity

Activity

IC50
Toxicity
26 µg/mL
Cytotoxic
IC50 | 26 | µg/mL | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
A novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics. | Int J Antimicrob Agents | 2018
Evidence 9 Activity

Activity

IC50
Toxicity
42 µg/mL
Cytotoxic
IC50 | 42 | µg/mL | target cell: Chinese hamster ovary cells CHO-K1

Target

Chinese hamster ovary cells CHO-K1

Source & Reference

NA
DBAASP
A novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics. | Int J Antimicrob Agents | 2018
Evidence 10 Activity

Activity

IC50
Toxicity
108 µg/mL
Cytotoxic
IC50 | 108 | µg/mL | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
A novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics. | Int J Antimicrob Agents | 2018
Evidence 11 Activity

Activity

IC50
Toxicity
17 µg/mL
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: CHO-K1: IC50=17 µg/ml PBMC: IC50=15 µg/ml

Target

erythrocytes

Source & Reference

NA
DRAMP
Int J Antimicrob Agents. 2018 Jul 52(1):52-62.
Evidence 12 Activity

Activity

IC50
Toxicity
16 µg/mL
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: CHO-K1: IC50=16 µg/ml PBMC: IC50=16 µg/ml

Target

erythrocytes

Source & Reference

NA
DRAMP
Int J Antimicrob Agents. 2018 Jul 52(1):52-62.
Evidence 13 Activity

Activity

IC50
Toxicity
23 µg/mL
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: CHO-K1: IC50=23 µg/ml PBMC: IC50=20 µg/ml

Target

erythrocytes

Source & Reference

NA
DRAMP
Int J Antimicrob Agents. 2018 Jul 52(1):52-62.
Evidence 14 Activity

Activity

IC50
Toxicity
25 µg/mL
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: CHO-K1: IC50=25 µg/ml PBMC: IC50=22 µg/ml

Target

erythrocytes

Source & Reference

NA
DRAMP
Int J Antimicrob Agents. 2018 Jul 52(1):52-62.
Evidence 15 Activity

Activity

IC50
Toxicity
40 µg/mL
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: CHO-K1: IC50=40 µg/ml PBMC: IC50=108.1 µg/ml

Target

erythrocytes

Source & Reference

NA
DRAMP
Int J Antimicrob Agents. 2018 Jul 52(1):52-62.